



Biological activities of *Punica granatum* L. and the emerging role of metabolomics in enhancing its therapeutic potential: A narrative review

Meharunnisa¹ , Fatima Rafique^{2,3*} 

¹Department of Obstetrics and Gynecology, National Institute of Unani Medicine, Bengaluru 560091, Karnataka, India

²Department of Moalajat, National Institute of Unani Medicine, Bengaluru 560091, Karnataka, India

³Current address: Hayat Unani Medical College, Lucknow 226101, Uttar Pradesh, India

***Correspondence:** Fatima Rafique, Hayat Unani Medical College, Lucknow 226101, Uttar Pradesh, India. frafiq786.fr@gmail.com

Academic Editor: Ivana Cacciatore, "G. d'Annunzio" University of Chieti-Pescara, Italy

Received: May 15, 2026 **Accepted:** July 5, 2026 **Published:** August 17, 2026

Cite this article: Meharunnisa, Rafique F. Biological activities of *Punica granatum* L. and the emerging role of metabolomics in enhancing its therapeutic potential: A narrative review. Explor Foods Foodomics. 2026;4:1010183. <https://doi.org/10.37349/eff.2026.1010183>

Abstract

Pomegranate has long been used in Greco-Arab medicine for gastrointestinal, cardiovascular, metabolic, and inflammatory disorders. It has been described to relieve nausea, vomiting, abdominal pain, diarrhoea, palpitations, etc. Modern scientific studies have validated these uses, attributing them to a rich phytochemical profile of polyphenols, flavonoids, anthocyanins, tannins, punicalagins, and ellagitannins. However, the precise mechanism of action and optimal application strategies for pomegranate in systemic diseases remain an area of investigation. Metabolomics provides a robust platform for elucidating the intricate relationships between pomegranate bioactives and human physiology. Therefore, to evaluate the therapeutic potential of pomegranate (*Punica granatum* L.) and find out how metabolomics can enhance its pharmacological applications, a literature review was conducted using ancient & modern pharmacology books, PubMed, Scopus, Web of Science, and Google Scholar. Human clinical trials were prioritized, followed by in vivo and in vitro studies. Evidence was synthesized qualitatively with emphasis on metabolomic findings. The research question was framed to determine whether metabolomics can enhance and optimize the therapeutic potential of pomegranate. Metabolomic studies demonstrated that pomegranate exhibits all its biological activities through gut microbiota-derived metabolites, particularly urolithins, which play a key role in mediating these effects. Therefore, it was concluded that integration of metabolomics with traditional pharmacology can enhance pomegranate-based therapeutics and support its role in precision nutrition.

Keywords

pomegranate, urolithins, ellagitannins, metabolomics, Unani medicine



Introduction

Pomegranate (*Punica granatum* L.) is one of the oldest known edible fruits belonging to the family Lythraceae [1, 2]. Its origin dates back to the Middle East, from where further cultivation led to the proliferation of its seeds in different regions of the world, resulting in a broad genetic diversity [3, 4]. The term pomegranate comes from the Latin word 'pomum', meaning apple, and 'granatus' meaning full of seeds [5]. The family Punicaceae contains a single genus, *Punica*, and two species, the most predominant one being *Punica granatum* L. (edible), and the less predominant *Punica protopunica* (inedible). It is often called 'the fruit of paradise' in the Middle East, due to its mention in the holy scriptures of the Bible and the Quran, with remarkable healing and medicinal properties. Classical texts document its use in gastrointestinal disorders, cardiovascular conditions, metabolic disturbances, and inflammatory diseases. These traditional claims have been supported by pharmacological research [6]. Despite this, a comprehensive understanding of how these compounds are metabolized and exert their effects in the human body is still evolving.

Metabolomics, a systems-level analytical approach, offers a powerful tool to elucidate these metabolic pathways, identify biomarkers of response, and enable personalized therapeutic strategies. It provides a snapshot of the metabolome and offers a holistic view of the biochemical changes occurring within a biological system in response to internal or external stimuli, such as dietary interventions [7]. Integrating metabolomic insights with traditional pharmacological studies of pomegranate has the potential to move beyond correlative observations to mechanistic understanding, thereby optimizing its therapeutic application.

This review aims to integrate Unani (Greco-Arab) knowledge with modern metabolomic insights to understand the therapeutic potential of pomegranate in systemic diseases.

Methods

Search strategy

Existing literature on pomegranate was collected and compiled from classical Unani as well as modern pharmacology books such as *Mufradat Azeezi*, *Qarabadeen Sarkari*, *Khazainul Advia*, *Wealth of India*, *Indian Materia Medica*, *Trease and Evans' Pharmacognosy*, etc. After that, a comprehensive literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar up to March 2026 using the keywords "*Punica granatum*", "pomegranate", "metabolomics", "ellagitannins", and "urolithins".

Inclusion criteria

Studies reporting pharmacological or clinical effects of pomegranate or investigating metabolomic mechanisms were included. Human clinical trials were prioritized, followed by in vivo and in vitro studies. Data were synthesized narratively with emphasis on mechanistic insights and clinical relevance.

Exclusion criteria

Papers having negative or neutral outcomes on pomegranate studies, or not focusing on pomegranate metabolomics, were excluded.

Discussion

Botanical description

Punica granatum L. is an evergreen deciduous spiny shrub that reaches up to 20 metres, mainly found in Persia, Arabia, Afghanistan, Baluchistan, and cultivated all over India [8, 9]. It has multiple irregular thorny branches with dark grey to brown colored bark. It has a red, leathery rind, in which seeds are encased in a pulp, sectioned by walls [8].

The leaves are bright green, 3–7 cm long, and 2 cm broad, glabrous, glossy, and leathery in appearance [2]. The flowers are 1–5 in quantity, and all of them are marginal except the one that grows terminally. These are short in size and are present without a peduncle. Flowers are funnel-shaped, bisexual, and

actinomorphic [3]. Fruits are large, round, brownish-yellow to red with a diameter of 5–12 cm, weighing 200 g to 800 g. It has an outer hard pericarp and an inner spongy mesocarp. Seeds are present in the mesocarp, usually of red or white color, entirely covered by arils, which are edible, juicy portions [2]. The plant grows in a wide range of climatic conditions, the most favourable one being hot, dry summers with deep sandy clay and high altitudes. The fruit is very sensitive to cold farming conditions, with the sweet ones more sensitive than the sour ones [3]. “*Bustani sheerin bedana*” from Kabul, Afghanistan, is described as the best variety, because its fruits are sweet (*‘sheerin’*) and without seeds (*‘bedana’*) [2, 3, 8]. Table 1 describes its taxonomical classification & vernaculars, whereas Table 2 describes its dosage as described in classical texts.

Table 1. Taxonomical classification & vernaculars of pomegranate.

Botanical name	<i>Punica granatum</i> L.	Dialect	Vernacular names
Kingdom	Plantae (Angiosperms)	English	Pomegranate [5, 9]
Division	Tracheophyta	Unani	Anar, Rumman, Gulnar, Gulnarfarsi [9]
Class	Magnoliopsida	Arabic	Rumman [4]
Order	Myrtales	Persian	Anar Tursa, Dulim, Dulima [1]
Family	Lythraceae [1, 5] Punicaceae [2, 3, 9]	Urdu	Anar [4]
Genus	<i>Punica</i>	Hindi	Anar [2]
Species	<i>Granatum</i> [2]	Sanskrit	Dadima [5], Raktabija, Madhubija, Suphala [4]

Table 2. Dosage of different parts of *Punica granatum* L. [4, 8, 10].

Part	Dose
Seeds	30–100 g
Juice	24–60 mL
Distillate	50–100 mL
Leaves	5–10 g

Ethnopharmacological uses

Pomegranate has been described to have various biological functions in Unani literature such as anti-emetic [4, 8, 11], anti-bile [8], digestive [8], appetizer [8], coolant [4, 8], cleansing [8], laxative [8], stomach, liver and heart tonic [4, 8, 10], anti-inflammatory [8], astringent [4, 8], hematinic [8], resolvent [10], mild diuretic [8, 10], aphrodisiac [8], anti-helminthic [8, 12], etc., details of which are given in Table 3 along with various compound formulations (*murak'kabat*) of pomegranate described in Unani literature.

Table 3. Functions of pomegranate are described in Unani literature & formulations.

S. No.	<i>Af'aal</i>	Action(s)	Use(s)	Part(s) used	Formulation
1	<i>Daaf-e-qay wa matli, daaf-e-qay'al-hamal</i> [8, 11, 13]	Antiemetic [4]	Nausea vomiting of pregnancy (NVP)	Fresh fruit juice	<i>Sharbat-e-Anar Sheerin</i>
2	<i>Daaf-e-hiddat safra</i>	Anti bilious [2, 9]	Bilious disorders	Juice, syrup	<i>Rubb e Anar</i>
3	<i>Hadim</i>	Digestive [2, 5, 9]	Dyspepsia, acidity	Fruit rind, juice, flowers	<i>Safoof-e-habb-ur-rummaan</i> [4]
4	<i>Muhallil-e-aurām</i>	Anti-inflammatory [2, 9]	Stomatitis, gastritis, colitis, ulcers	Leaves, seeds' juice, fruit rind	<i>Barud-e-rummaan</i>
5	<i>Qabid</i>	Astringent [2, 5, 9]	Diarrhea, dysentery, uterine disorders, leucorrhea, urinary incontinence	Fruit rind, seeds' juice, flowers, bark	<i>Safoof-e-habb-ur-Rumman</i> [4]
6	<i>Mudir-e-baul khafeef</i> [8, 10]	Mild diuretic	Urinary infections	Seeds	<i>Sharbat-e-Anar Sheerin</i>

Table 3. Functions of pomegranate are described in Unani literature & formulations. (continued)

S. No.	Af'aal	Action(s)	Use(s)	Part(s) used	Formulation
7	<i>Dafe-attach</i>	Anti-thirst [2, 4, 9]	Excessive thirst	Fresh juice	<i>Sharbat-e-Anar Sheerin</i>
8	<i>Mubarrid, daafe bukhar</i>	Refrigerant, antipyretic [2, 9]	Night sweats, malaria and seasonal fevers	Stem & root bark, juice, syrup	<i>Sharbat Anar Tursh</i>
9	<i>Mukhrij-e-balgham</i>	Expectorant [2, 5, 9]	Cough, bronchitis, whooping cough	Powdered flower & buds	<i>Habb-e-Hindi Suaal</i> [4]
10	<i>Muqawwi-e-bah</i>	Aphrodisiac [5]	Sexual debility [14]	Flowers	<i>Jawarish anar murakkab</i>
11	<i>Mudammil e qurooh</i>	Cicatrizing [5, 15]	Wounds	Flowers	<i>Barud-e-rummaan</i>
12	<i>Muqawwi-e-aam</i>	General tonic, antioxidant [5, 15]	Greying of hairs, anxiety, Alzheimer's disease [16]	Flowers, seeds	<i>Mufarrah Azam Jawahar</i>
13	<i>Daafe afoonat</i>	Antimicrobial [2, 9, 15, 17]	Infections [18, 19]	Flowers	<i>Safoof Gulnar</i>
14	<i>Muwallide-khoon</i> [8]	Hematinic [15]	Anemia	Fruit	<i>Sharbat Anar Sheerin</i>
15	<i>Qatil kirm-e-shikam</i>	Anti-helminthic [9]	Helminthiasis	Root bark	<i>Dawae anar</i>
16	<i>Habis ud dam</i>	Hemostatic [4]	Bleeding disorders [15, 20, 21]	Rind, flowers	<i>Sufoof Istehaza</i> [22]
17	<i>Mushtahi</i> [8]	Appetizer	Anorexia	Fruit	<i>Jawarish Anarain</i> [23]
18	<i>Muqawwi meda, jigar wa qalb</i> [4, 8, 10]	Stomach, liver & heart tonic [2, 5, 9]	Diabetes [24], hypertension [25], palpitations [26]	Fruit, flowers, plants	<i>Safoof-e-Ziabetus Dolabi</i> [27]

Results

Nutritional value and phytochemistry

One hundred grams of raw pomegranate fruit provides approximately 68–83 calories, 17–19 g of carbohydrates, 4 g of fiber, 1.7 g of protein, and various other vitamins and minerals [15] as listed in Table 4. It contains a diverse array of bioactive compounds, including ellagitannins (punicalagin, punicalin), flavonoids (quercetin, kaempferol), anthocyanins, alkaloids, and organic acids [15]. These constituents are distributed across different plant parts, including peel, seeds, juice, flowers, and bark, as shown in Table 5.

Table 4. Pomegranate's nutrient values for 100 g of raw edible portion.

Composition	Value/100 g	Units	Composition	Value per 100 g	Units
Water	77.93	g	Magnesium	12	mg
Energy	83	kcal	Copper	0.158	mg
Protein	1.67	g	Selenium	0.5	mg
Total lipid	1.17	g	Vitamin K	16.4	mcg
Carbohydrates	18.7	g	Vitamin C	10.2	mg
Fiber	4.0	g	Folate	38	mcg
Phosphorus	36	mg	Pantothenic acid	0.377	mg
Iron	0.3	mg	Vitamin B1	0.067	mg
Potassium	236	mg	Vitamin B2	0.053	mg
Calcium	10	mg	Vitamin B3	0.293	mg
Sodium	3.0	mg	Vitamin B6	0.075	mg

Adapted from United States Department of Agriculture (USDA) national nutrient database for standard reference (<https://fdc.nal.usda.gov/food-details/2727588/nutrients>).

Table 5. Chemical constituents of *Punica granatum* L.

Chemical constituents	
Peel [2, 3, 9, 15, 28–32] Ellagic acid, caffeic acid, ellagitannins, isopelletierine, methylpelletierine, chlorogenic acid, cinnamic acid, pseudopelletierine, o-coumaric acid, p-coumaric acid, luteolin, kaempferol, quercetin, gallic acid, punicalin, punicalagin, catechins, hydroxy benzoic acid, tannin (26%), anthocyanidins, flavonols, rutin, polyphenols, flavonoids.	Juice [15, 28–31, 33] Ellagic acid, flavonols, aliphatic organic acids, gallic acid, amino acids, epigallocatechin gallate (EGCG), polyphenols, flavonoids, ascorbic acid, quinic acid, anthocyanins, organic acids, caffeic acid, quercetin, rutin, catechin, glucose, fructose, sucrose, iron.
Root and bark [2, 9, 15, 28–32] Ellagitannins, pelletierine, isopelletierine, tannin (22–25%), punico-tannic acid (20–25%), mannite, sugar gum, pectin, ash (15%), piperidine alkaloids, pyrrolidine alkaloid, punicalin, alkaloids, polyphenols, flavonoids.	Flower [9, 15, 28, 29, 31, 33] Gallic acids, ursolic acid, triterpenoids, fatty acids, pelargonidine-3,5-di-glucoside, sitosterol, sitosterol-beta-D-glucoside, maslinic acid, asiatic acid, polyphenols, fatty acids, punicalagin, punicalin.
Leaves [3, 9, 15, 28, 29, 31, 33] Tannins (11%), carbohydrates, sterols, saponins, ellagitannins, flavonoids, piperidine alkaloids, glycosides, ellagitannins (granatins A, B and punicafofin), luteolin, fatty acids, punicalagin, punicalin, ellagic acid, resins, iron, magnesium sulfate, potassium, sodium.	Seeds [2, 4, 9, 15, 28–32] Tannin (28%), punicic acid, methylellagic acid, Tri-o-methylellagic acid, oleic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, sterols, tocopherol, malvidin pentose glycoside, ellagic acid, fatty acids, carbohydrates, iron, chloride, calcium, sodium, potassium, phosphate.

Pharmacological studies on pomegranate

Cardiovascular diseases

Pomegranate has been extensively studied for its cardioprotective effects, including reducing blood pressure, improving lipid profiles, and attenuating atherosclerosis [34].

Human clinical trials: A randomized, double-blind, placebo-controlled trial investigated the effect of pomegranate juice consumption on cardiovascular risk factors in patients with type 2 diabetes. Metabolomic analysis of plasma revealed significant changes in lipid metabolism, including a reduction in oxidized low-density lipoprotein (LDL) and an increase in beneficial high-density lipoprotein (HDL) cholesterol subfractions, alongside alterations in amino acid profiles indicative of improved endothelial function [35]. Another study using metabolomics in hypertensive subjects showed that pomegranate extract supplementation led to changes in pathways related to nitric oxide synthesis and arginine metabolism [36].

In vivo studies: Animal models of atherosclerosis have demonstrated that pomegranate supplementation alters circulating lipid species and inflammatory markers [37], as identified by metabolomics, suggesting a multi-targeted approach to reduce plaque formation [38].

In vitro studies: Urolithins derived from pomegranate modulate cellular metabolic pathways involved in inflammation and oxidative stress, thereby protecting against endothelial dysfunction by inhibiting the growth of pathogenic *Clostridia* and *Staphylococcus aureus* and maintaining a healthy gut microbiome [39].

Metabolic syndrome and diabetes

Pomegranate has shown promise in managing metabolic syndrome, including insulin resistance, dyslipidemia, and obesity [40].

Human clinical trials: A clinical trial investigating the effects of pomegranate extract in obese individuals found improvements in insulin sensitivity and glucose metabolism. Plasma metabolomics identified changes in fatty acid metabolism, branched-chain amino acids, and bile acid profiles, suggesting a role for pomegranate in modulating key pathways related to insulin signaling and energy homeostasis [41]. Another study in patients with type 2 diabetes reported that pomegranate consumption reduced total cholesterol, LDL-cholesterol, and total cholesterol, which reduces the risk of heart disease in hyperlipidemic and diabetic patients [42].

In vivo studies: In diet-induced obese mice, pomegranate administration led to alterations in hepatic lipid metabolism and systemic inflammation, revealing a normalization of several metabolic pathways, including fatty acid synthesis and oxidation [43].

In vitro studies: Studies on adipocytes and hepatocytes have shown that pomegranate bioactives influence glucose uptake, lipogenesis, and mitochondrial function, with metabolomics confirming shifts in key metabolic intermediates [44].

Neurodegenerative diseases

The antioxidant and anti-inflammatory properties of pomegranate suggest its potential in neuroprotection, particularly against Alzheimer’s and Parkinson’s disease [45].

In vivo studies: In animal models of Alzheimer’s disease, pomegranate extract supplementation improved cognitive function and reduced amyloid plaque burden. Brain metabolomic analysis revealed changes in neurotransmitter levels, energy metabolism, and oxidative stress markers, suggesting a direct neuroprotective effect [46]. Similarly, in Parkinson’s models, pomegranate intervention modulated dopamine metabolism and attenuated neuroinflammation, as evidenced by metabolomic shifts in brain tissue [47].

In vitro studies: Neuronal cell lines have shown that urolithins protect against oxidative damage and apoptosis by modulating mitochondrial function and intracellular signaling pathways, identifiable through metabolomic changes [48].

Cancer

Pomegranate has demonstrated anti-cancer properties across various cancer types, including prostate, breast, and colon cancer, primarily through mechanisms involving cell cycle arrest, apoptosis induction, and inhibition of angiogenesis [49].

Human clinical trials: A phase II clinical trial in prostate cancer patients reported that pomegranate extract consumption significantly prolonged prostate-specific antigen doubling time [50].

In vivo studies: In xenograft models of prostate cancer, pomegranate extract inhibited tumor growth and metastasis. The tumor tissue and plasma revealed that pomegranate extracts reduced tumor cell volume, weight, viability, migration, and proliferation. The antitumor effects of the extracts and hydrolysates may be attributed not only to intact proteins and peptides but also to the co-extracted phenolic compounds [51].

In vitro studies: Various cancer cell lines have shown that pomegranate compounds induce apoptosis and inhibit proliferation by modulating key metabolic pathways, such as glycolysis and fatty acid synthesis, as revealed by targeted and untargeted metabolomics [52].

Table 6 summarizes various traditional remedies using pomegranate in different diseases and their clinical correlation. Figure 1 depicts the phytoconstituents and pharmacological actions of *Punica granatum* L. in a concise manner.

Table 6. Applications of pomegranate in various traditional medicines with clinical correlation.

Disease	Remedies in traditional medicine	Related studies	Reference(s)
Diseases of the head, neck and throat	- Boil pomegranate rind in alcohol until it becomes soft, and apply its bandage around the ear to resolve otitis externa [12]. - Fruit distillate mixed with honey and used as an ear drop relieves otalgia [12]. - Use of the seeds or peels’ decoction as a mouthwash strengthens the gums and prevents bleeding [12].	Wound healing activity: <i>Punica granatum</i> L. flower extract, when applied to skin injuries induced by burns in rats, effectively decreased the wound size and induced fast healing.	Nasiri et al. (2017) [53]
Cardiovascular disorders	Fruit distillate mixed with pomegranate pulp given along with <i>Terminalia bellirica</i> relieves palpitations and weakness of the heart due to choleric temperament [54].	Cardioprotective activity: <i>Punica granatum</i> L. extract reduces inflammatory markers and blood pressure among older adults and promotes healthy aging.	Farhat et al. (2025) [55]

Table 6. Applications of pomegranate in various traditional medicines with clinical correlation. (continued)

Disease	Remedies in traditional medicine	Related studies	Reference(s)
Diseases of the eye	- Oral use of one flower bud daily for one year is effective in ocular pain [8, 9, 12]. - Green leaves of the pomegranate tree, made into a paste and applied to the eyes, help treat conjunctivitis [8, 9, 12].	Anti-inflammatory activity: Topical application of pomegranate rind extract had significant anti-inflammatory effects on the skin, ameliorating cold sores and herpetic stromal keratitis.	Houston et al. (2017) [56]
Gastro-intestinal disorders	- Use of pomegranate water mixed with sugar relieves nausea [12]. - Paste made up of pomegranate flowers and fresh grape leaves, applied over the abdomen, stops severe vomiting [9]. - Pill prepared from sour pomegranate seeds, 36 g, long pepper, 18 g, black pepper, 5 g, potassium carbonate, 4 g, and sugar, given in a dose of 2–3 g twice daily, relieves dyspepsia [8]. - Use of pomegranate water with honey is helpful in diarrhea [12]. - Oral use of <i>usara-e-anar</i> (350 g) with sugar (50 g) is helpful in the expulsion of collected bile from the intestines [9]. - Decoction prepared from pomegranate bark, 24 g, and mulberry, 24 g acts as anthelmintic [12]. - The fresh root bark, 56 g, sliced & boiled in 946 mL of water, reduced to 473 mL and strained, used empty stomach in the morning every half-hour till 4 doses are taken, and then ingesting castor oil expels intestinal worms effectively [8].	Anti-emetic activity: Pomegranate and spearmint syrup have been found effective in NVP. Peel extract of <i>Punica granatum</i> L. exhibited antiemetic activity. Antidiarrheal activity: <i>Punica granatum</i> L. peels showed similar efficacy as loperamide in an in vitro study. Anti-helminthic activity: Extracts of bark and root of <i>Punica granatum</i> L. showed potential anthelmintic activity in an in vitro study.	Abdolhosseini et al. (2017) [57] Ishtiyag and Abbas (2018) [58] Qnais et al. (2007) [59] Baravkar et al. (2020) [60]
Diseases of the reproductive system	- Sitz bath with the decoction of bark peel is useful in heavy menstrual bleeding and leucorrhea [12]. - Pomegranate reduces the chances of premature and low birth weight infants [5].	Hypo androgenic activity: Pomegranate juice improves insulin resistance, BMI & WC in PCOS. Neuroprotective property: Pomegranate juice helps protect against brain injury in IUGR babies.	Esmaeilinezhad et al. (2019) [61] Ross et al. (2021) [62]
Skin diseases	- Pomegranate imparts a glow to the face as it enhances the quality and quantity of blood [8, 12]. - Sprinkling skin wounds with the fine powdered bark helps in fast healing [12]. - In South Anatolia, Turkey, some people employ the ashes of the fruit peel as a protection against skin infections [9, 15].	Hemopoietic activity: Pomegranate juice improved the erythrocytes & mean corpuscular hemoglobin levels. Antioxidant activity: Pomegranate peel extract acts as a potent free radical scavenger in albino rats.	Manthou et al. (2017) [63] Chidambara et al. (2002) [64]
Bleeding disorders	- The juice of pomegranate flower & doob grass (<i>Cynodon dactylon</i>), both in equal quantity, is useful in epistaxis, hemorrhages, ulcers of the uterus & rectum [9]. - Applying paste of the rind over the chest is helpful in hemoptysis.	Anti-hemorrhagic activity: <i>Punica granatum</i> flower is as effective as tranexamic acid in heavy menstrual bleeding.	Es-Haghee Ashteani et al. (2023) [65] Goshtasebi et al. (2015) [66]

NVP: nausea vomiting of pregnancy; BMI: body mass index; WC: waist circumference; PCOS: polycystic ovarian syndrome; IUGR: intra-uterine growth retardation.

Understanding the metabolomics perspective of pomegranate bioactives

The therapeutic effects of pomegranate are closely linked to its unique phytochemical composition and metabolism. Punicalagins, the most abundant ellagitannins, are hydrolyzed in the gut into ellagic acid, which is further metabolized by gut microbiota into urolithins (e.g., urolithin A, B, C, D) [67]. These urolithins are considered key bioactive metabolites responsible for many of pomegranate's observed health benefits [68], including anti-inflammatory and antioxidant activities [69]. They exhibit higher bioavailability than the parent compounds, possess anti-inflammatory and antioxidant properties, and influence cellular metabolism and signaling pathways.




Figure 1. The phytoconstituents and pharmacological actions of *Punica granatum L.*

The bioavailability and subsequent biological activity of these metabolites are highly dependent on individual gut microbiome composition, highlighting a critical area where metabolomics can provide personalized insights [70].

Other important compounds include anthocyanins (e.g., delphinidin, cyanidin, petunidin glycosides), which contribute to the fruit's vibrant color and possess significant antioxidant capacities [6]. Flavonoids, such as quercetin and kaempferol, and ellagitannins also play a role in its overall bioactivity. Metabolomic studies have identified alterations in lipid metabolism, modulation of amino acid pathways, and changes in gut microbiota-derived metabolites. Importantly, inter-individual variability in gut microbiota leads to different "metabotypes", influencing therapeutic outcomes.

Table 7 compiles key studies on metabolomics applied to pomegranate (*Punica granatum L.*), focusing on metabolite profiling, identification of bioactive compounds (e.g., ellagitannins, urolithins, polyphenols), and their pharmacological implications. Metabolomics techniques such as proton nuclear magnetic resonance (1H-NMR), liquid chromatography-mass spectrometry (LC-MS), ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS), and gas chromatography-mass spectrometry (GC-MS) are highlighted.

Table 7. Compilation of studies on pomegranate metabolomics.

S. No.	Short study title	Key methods	Main findings	Relevance	Author/Year
1	Metabolic profiling and untargeted 1H-NMR-based metabolomics study of different Iranian pomegranate ecotypes	1H-NMR and 2D-NMR spectroscopy for untargeted metabolomics; comparison across Iranian ecotypes.	Identified variations in anthocyanins, ellagic acid derivatives and other metabolites. Bajestan, Ferdows, and Yazd ecotypes showed higher anthocyanin & ellagic acid levels.	Demonstrates geographical & varietal differences in pomegranate metabolome, aiding breeding of bioactive-rich cultivars.	Hasanpour et al. (2020) [71]
2	Study of nutritional quality of pomegranate juice using 1H NMR-based metabolomic approach: A comparison between conventionally & organically grown fruits	1H-NMR metabolomics coupled with multivariate analysis; comparison of conventional vs. organic juices.	Organic juices showed enhanced levels of bioactive molecules. Clear divergences in metabolomic profiles, with organic cultivation improving nutraceutical properties.	Highlights cultivation impacts on pomegranate juice metabolome, supporting organic farming.	Villa-Ruano et al. (2020) [72]
3	Development of a new extraction method for pomegranate and metabolite profiling by a LC-MS & 1H NMR combined approach	LC-ESI/MS and 1H-NMR; solid-liquid dynamic extraction (SLDE-Naviglio) with ethanol.	Extract from peel using SLDE-Naviglio was richest in hydrolysable tannins, flavonoids, ellagic acid & phenol glucosides. Ethanol-juice mixture yielded the highest phenolic, tannin, & flavonoid.	Optimizes green extraction for metabolomics, revealing bioactive enrichment in pomegranate by-products.	Polcaro et al. (2024) [73]
4	Evaluation of morphological, qualitative, and metabolomic traits during fruit ripening in pomegranate	NMR-based metabolomics; physico-chemical analysis during ripening stages.	Ripening altered anthocyanins, polyphenols, and sugars; NMR identified metabolic shifts linked to color, size, and flavor.	Maps temporal metabolomic dynamics, informing harvest timing for optimal bioactive content.	Cirillo et al. (2022) [74]
5	Metabolomic NMR analysis and organoleptic perceptions of pomegranate wines: Influence of cultivar and yeast on the product characteristics	NMR metabolomics; sensory analysis of wines from different cultivars and yeasts.	Cultivar-specific profiles in polyphenols and volatiles; yeast influenced urolithin precursors and flavor compounds.	Extends metabolomics to fermented pomegranate products, linking metabolites to sensory quality.	Girelli et al. (2023) [75]
6	Phytochemical composition of methanolic extract of pomegranate flower petals by GC-MS	GC-MS for methanolic extract of flower petals.	Identified squalene and gallic acid as major compounds; eight peaks revealed diverse secondary metabolites.	Early GC-MS profiling of floral metabolome for medicinal uses.	Hendre et al. (2012) [76]
7	Ultra-HPLC–MSn (Poly)phenolic profiling and chemometric analysis of juices from ancient <i>Punica granatum</i> L. cultivars: A nontargeted approach	UHPLC–MSn with chemometrics for ancient cultivar juices.	Diverse phenolic profiles; chemometrics clustered cultivars by metabolite patterns, including ellagitannins.	Nontargeted approach for biodiversity in pomegranate metabolome.	Calani et al. (2013) [77]
8	GC-MS analysis of phytochemical constituents in ethanolic extract of <i>Punica granatum</i> peel and <i>Vitis vinifera</i> seeds	GC-MS for ethanolic peel extract.	Detected ethyl acetate, pentanoic acid, succinamic acid; high antioxidant potential.	Focuses on peel metabolome, linking to antimicrobial properties.	Kumar and Vijayalakshmi (2011) [78]
9	Influence of drought stress on increasing bioactive compounds of pomegranate juice. Exploratory study using LC–MS-based untargeted metabolomics approach	UHPLC–QTOF–MS untargeted metabolomics under irrigation levels.	Drought increased secondary metabolites (e.g., ellagitannins); first UHPLC–QTOF study on irrigation effects.	Stress-induced metabolomic changes for resilient, bioactive-rich cultivars.	Gómez-Bellot et al. (2023) [79]
10	Antimicrobial activity and bio-active compounds analysis in	GC-MS for peel ethanolic extract; antifungal assays.	Identified major phytochemicals; strong inhibition against <i>Candida</i> and	Links metabolomics to antimicrobial bioactivity in peel.	Attia (2019) [80]

Table 7. Compilation of studies on pomegranate metabolomics. (continued)

S. No.	Short study title	Key methods	Main findings	Relevance	Author/Year
	ethanolic plant extract of <i>Punica granatum</i> using GC-MS		filamentous fungi.		
11	Profiling phenolic composition in pomegranate peel from nine selected cultivars.	UHPLC-QTOF-MS and UPLC-QQQ-MS for peel phenolics.	Comprehensive phenolic map across cultivars; high ellagitannin diversity.	Cultivar-specific peel metabolomics for bioactive selection.	Man et al. (2022) [81]
12	Liquid chromatography coupled with tandem MS for phenolic characterization of pomegranate fruit & flower extracts used as botanical dietary supplements	LC-TOF-MS/MS for fruit and flower extracts.	Identified 21 phenolics in fruit (including new ellagitannin pomellatannin) and 15 in flowers	Metabolomics for supplement standardization.	Liu et al. (2018) [82]
13	The main components identified by GC-MS in the petroleum ether extract of pomegranate peel	GC-MS for petroleum ether peel extract.	Key components linked to insecticidal activity; reduced enzyme activity in treated larvae.	GC-MS for bioactive screening in peel against pests.	Farag et al. (2021) [83]
14	A comprehensive study of pomegranate flower polyphenols and metabolites in rat biological samples by HPLC-QTOF-MS	HPLC-QTOF-MS for flower metabolites in rat plasma/urine.	Detected polyphenols and metabolites post-administration.	In vivo metabolomics of flowers.	Yisimayili et al. (2019) [84]
15	A review on phytochemicals, metabolic profiles & pharmacokinetic studies of the different parts of pomegranate.	Review of LC-HRMSn for multi-part metabolomics.	Comprehensive profiles across plant parts; pharmacokinetics of ellagitannins/urolithins.	Holistic review of pomegranate metabolome.	Yisimayili and Chao (2022) [85]
16	The gut microbiota metabolism of pomegranate ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers	UPLC-ESI-QTOF-MS for urine metabolomics; intervention with pomegranate extract/nuts.	Two metabotypes (UM-A, UM-B); UM-B linked to higher cholesterol/LDL; UM-A protective.	Links urolithin production to cardiometabolic health via metabolomics.	Selma et al. (2018) [86]
17	Targeted metabolic profiling of pomegranate polyphenols & urolithins in plasma, urine & colon tissues from colorectal cancer (CRC) patients	HPLC-ESI-QTOF-MS/MS for ET/urolithin profiling post-pomegranate intake.	Detected EA conjugates and 12 urolithins in colon tissues; potential CRC biomarkers.	Tissue-specific urolithin metabolomics in cancer patients.	Nuñez-Sánchez et al. (2014) [87]
18	Urolithins: A comprehensive update on their metabolism, bioactivity, and associated gut microbiota	Review of metabolomics (LC-MS/NMR) on urolithin production.	Urolithins as pleiotropic bioactives; microbiota-dependent metabotypes.	Updates urolithin metabolomics from ET sources like pomegranate.	García-Villalba et al. (2022) [88]
19	Urolithins, intestinal microbial metabolites of pomegranate ETs, exhibit potent antioxidant activity in a cell-based assay	Cell-based antioxidant assays; LC-MS for urolithin identification.	Urolithin A/B showed strong antioxidant potency (IC_{50} ~13.6 μ M).	Mechanistic metabolomics linking urolithins to pomegranate's antioxidant effects.	Bialonska et al. (2009) [89]
20	Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: The evidence so far	Review of in vitro metabolomics on urolithin bioactivity.	Urolithins mediate anti-inflammatory/anticancer effects; better absorbed than EA.	Evidence for urolithins as key pomegranate metabolites.	Espín et al. (2013) [90]
21	Pomegranate's ellagitannins:	Review of urolithin pathways (Nrf2, HO-1	Urolithins localize in prostate/colon; anti-cancer via	Metabolic pathways of ellagitannins to	Benedetti et al. (2023) [91]

Table 7. Compilation of studies on pomegranate metabolomics. (continued)

S. No.	Short study title	Key methods	Main findings	Relevance	Author/Year
	metabolism and mechanisms of health promoting properties	activation).	phase II conjugates.	urolithins.	
22	Pomegranate ellagitannins	Pharmacokinetics via LC-MS; urolithin conjugation studies.	Urolithins persist in urine up to 48 h; prostate localization.	Bioavailability metabolomics of ETs.	Kmail (2006) [92]
23	EA recovery by solid state fermentation of pomegranate wastes by <i>Aspergillus niger</i> & <i>Saccharomyces cerevisiae</i> : A comparison	HPLC for EA post-fermentation; ultrasound/microwave extraction.	<i>S. cerevisiae</i> yielded 12% EA from wastes; fungal tannase hydrolyzes ETs.	Biotechnological metabolomics for EA/urolithin precursors.	Moccia et al. (2019) [93]
24	Pomegranate ET-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation	In vitro assays with BV-2 microglia/SH-SY5Y neurons; LC-MS for urolithins.	Urolithins reduced neuroinflammation; potential AD protection.	Urolithin metabolomics in neuroprotection.	DaSilva et al. (2019) [94]
25	Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, & host health status	Review of metabotypes via LC-MS interventions	Three urolithin metabotypes; dysbiosis links to health risks.	Metabotype classification in pomegranate consumption.	Tomás-Barberán et al. (2017) [95]
26	Direct supplementation with urolithin A overcomes limitations of dietary exposure & gut microbiome variability in healthy adults to achieve consistent levels across the population	Intervention with urolithin A; plasma/urine LC-MS.	Supplementation ensures consistent levels despite microbiome variability; 40% produce UA from diet.	Bypassing gut metabolomics variability.	Singh et al. (2022) [96]
27	Absorption and metabolism of Urolithin A and ellagic acid in mice and their cytotoxicity in human colorectal cancer cells	Comparative metabolomics (LC-MS); in vivo mouse model.	Urolithin A derivatives cytotoxic to CRC cells; gut microbiota key for transformation.	Mouse metabolomics of urolithins.	Lin et al. (2023) [97]
28	Pomegranate ETs stimulate the growth of <i>Akkermansia muciniphila</i> in vivo	16S rRNA sequencing; urolithin LC-MS post-extract.	70% participants produced urolithin A, which correlated with <i>A. muciniphila</i> abundance.	Microbiota-metabolite interactions.	Henning et al. (2017) [98]
29	Urolithins: The gut-based metabolites of ellagitannins in cancer prevention.	Review of LC-MS on urolithins in cancer models.	Urolithins arrest cell cycle/induce apoptosis in bladder/prostate cancers.	Anticancer urolithin metabolomics.	Al-Harbi et al. (2021) [99]
30	Pomegranate extract induces ellagitannin metabolite formation & changes stool microbiota in healthy volunteers	4-week 1,000 mg pomegranate extract; urinary/fecal urolithin A profiling.	Three metabotype groups; microbiota modulation in responders.	Intervention metabolomics and microbiota shifts.	Li et al. (2015) [100]
31	Neuroprotective effects of pomegranate juice against Parkinson’s disease & presence of ellagitannins-derived metabolite-urolithin A in the brain	Rotenone PD rat model; LC-MS for brain urolithin A.	Pomegranate juice reduced motor deficits/ α -synuclein; urolithin A in midbrain.	Brain metabolomics in PD.	Kujawska et al. (2019) [101]
32	Pomegranate juice & extracts provide similar levels of plasma &	Crossover with pomegranate juice, liquid extract, & powder	Equivalent urolithin-A glucuronide (~1,000 ng/mL); powdered extract showed	Comparative metabolomics of juice vs. extracts.	Seeram et al. (2008) [102]

Table 7. Compilation of studies on pomegranate metabolomics. (continued)

S. No.	Short study title	Key methods	Main findings	Relevance	Author/Year
	urinary ET metabolites in humans	extract; LC-MS for metabolites.	delayed peak.		
33	Ellagitannins	Review of ET digestion/metabolism to urolithins via LC-MS/NMR.	ETs hydrolyzed to EA, then urolithins; three phenotypes in trials.	Overview of ET metabolomics pathways.	Nasef et al. (2023) [103]

1H-NMR: proton nuclear magnetic resonance; 2D: 2 dimensional; LC-MS: liquid chromatography-mass spectrometry; ESI: electrospray ionization; SLDE: solid-liquid dynamic extraction; GC-MS: gas chromatography-mass spectrometry; UHPLC-MSn: ultra-high performance liquid chromatography-multistage mass spectrometry; UHPLC-QTOF-MS: ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry; QQQ: triple quadrupole; ET: ellagitannins; EA: ellagic acid; IC: inhibitory concentration; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase 1; BV-2: immortalized murine cell line; SH-SY5Y: human derived neuroblastoma cell line; AD: Alzheimer's disease; rRNA: ribosomal ribonucleic acid; PD: Parkinson's disease.

Pomegranate derived exosomes

Recent studies have highlighted the therapeutic potential of pomegranate-derived exosome-like nanoparticles as natural nanocarriers capable of delivering bioactive molecules. These vesicles contain a diverse array of phytochemicals, lipids, proteins, and regulatory RNAs that can modulate multiple cellular pathways [104]. Experimental evidence suggests that these exosomes exhibit anti-inflammatory, antioxidant, and immunomodulatory activities [105], making them promising for the management of inflammatory bowel disease, liver disorders, metabolic syndrome, and cardiovascular diseases. Furthermore, pomegranate exosomes have demonstrated the ability to influence macrophage polarization, reduce oxidative stress, promote tissue repair, and inhibit the progression of certain cancers through the regulation of cell proliferation, apoptosis, and angiogenesis [105]. Although most findings remain at the preclinical stage, pomegranate-derived exosomes represent an emerging and innovative approach in nanomedicine, offering a novel platform for the prevention and treatment of diverse pathological conditions.

Conclusion

Punica granatum L. represents a valuable intersection between traditional Unani medicine and modern pharmacology. While its therapeutic potential is well established in traditional Unani medicine, variability in metabolism and bioavailability limits its clinical translation. Metabolomics can help overcome these challenges by enabling mechanistic understanding, biomarker discovery, and personalized therapeutic strategies. Future research integrating multi-omics approaches and well-designed clinical trials is essential to fully harness their potential in precision medicine. Table 8 enlists the level of evidence provided by various sources used in this paper for the ethnopharmacological, phytochemical, and metabolomic research on pomegranate. Figure 2 illustrates the entire gist of this paper.

Table 8. Level of evidence of various studies of *Punica granatum* L.

Evidence level Key findings		Strength of evidence
Traditional use	Cardiovascular and gastrointestinal benefits	Historical/Ethnomedicinal
In vitro studies	Antioxidant, anti-inflammatory, antiproliferative effects	Mechanistic
In vivo studies	Hepatoprotective, cardioprotective, neuroprotective effects	Moderate
Clinical studies	Improvements in blood pressure, lipid profile, glycemic markers	Strongest available but still limited for some outcomes

Technical limitations of metabolomics

The metabolome is highly dynamic and sensitive to age, sex, diet, circadian rhythm, environmental exposures, medication use, and gut microbiota composition, making it difficult to distinguish treatment-




Figure 2. Pomegranate metabolomics to integrate traditional and modern pharmacology.

specific effects. Sample collection, storage, extraction procedures, and analytical workflows can introduce substantial analytical variability, affecting reproducibility across studies. Furthermore, no single analytical platform can comprehensively capture the entire metabolome. Nuclear magnetic resonance (NMR) spectroscopy offers high reproducibility and minimal sample preparation but has relatively low sensitivity, whereas mass spectrometry (MS)-based approaches, including LC-MS and GC-MS, provide greater sensitivity but are susceptible to ion suppression, matrix effects, and instrument-dependent variability. Data processing and interpretation are also challenging, as untargeted metabolomics generates large, complex datasets that require sophisticated tools and approaches, increasing the risk of false-positive discoveries.

In the context of pomegranate research, inter-individual differences in gut microbial metabolism further complicate interpretation, as the conversion of ellagitannins into bioactive urolithins varies considerably among individuals. Additionally, most studies are cross-sectional or short-term with relatively small sample sizes, limiting the establishment of causal relationships between metabolomic alterations and clinical outcomes. Future advances in standardized protocols, high-resolution analytical platforms, integrated multi-omics approaches, improved metabolite databases, and large-scale longitudinal studies will be essential to overcome these limitations and fully realize the potential of metabolomics in optimizing pomegranate-based therapeutics.

Abbreviations

1H-NMR: proton nuclear magnetic resonance

GC-MS: gas chromatography-mass spectrometry

LC-MS: liquid chromatography-mass spectrometry

LDL: low-density lipoprotein

UHPLC-QTOF-MS: ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry

Declarations

Acknowledgments

The authors are thankful to Professor Abdul Wadood, former director, National Institute of Unani Medicine, Bengaluru, for giving us the opportunity to explore this medicinal fruit plant, and Mr. Ehtesham Ahmed, librarian, National Institute of Unani Medicine, Bengaluru, for providing all the required classical Unani textbooks for the literature review. During the preparation of this work, the author(s) used ChatGPT to generate Figure 1 and NotebookLM for creating Figure 2. After using the tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

Author contributions

MN, FR: Conceptualization, Data curation, Visualization, Formal analysis. MN: Writing—original draft. FR: Writing—review & editing. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

© The Author(s) 2026.

Publisher's note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

1. Kumari I, Kaurav H, Chaudhary G. Punica granatum L. (Dadim), Therapeutic Importance of World's Most Ancient Fruit Plant. J Drug Deliv Ther. 2021;11:113–21. [\[DOI\]](#)
2. Tempany H. The Wealth of India. In: A Dictionary of Indian Raw Materials and Industrial Products. 8th Vol. New Delhi: NISCAIR; 2009. pp. 317–24.
3. Shaygannia E, Bahmani M, Zamanzad B, Rafieian-Kopaei M. A Review Study on Punica granatum L. J Evid Based Complementary Altern Med. 2016;21:221–7. [\[DOI\]](#) [\[PubMed\]](#)
4. The Unani Pharmacopoeia of India. New Delhi: Department of AYUSH, Ministry of Health & Family Welfare; 2007.

5. Swetha D, Krishna Mohan G. New insights on *Punica Granatum* L: Ancient knowledge to current research. *Indian Drugs*. 2013;50:5–23. [\[DOI\]](#)
6. Jurenka J. Therapeutic applications of pomegranate (*Punica granatum* L.): a review. *Altern Med Rev*. 2008;13:128–44.
7. Wishart DS. Metabolomics: applications to food science and nutrition research. *Trends Food Sci Technol*. 2008;19:482–93. [\[DOI\]](#)
8. Ghani N. *Khazainul Advia*. New Delhi: Idara Kitab ul Shifa; 2011.
9. Nadkarni KM. *Indian Materia Medica*. Vol. 1st, 2nd. Mumbai: Popular Prakashan Pvt (Ltd); 2009.
10. Hakim MAHL. *Mufradat e Azizi*. New Delhi: CCRUM; 2009.
11. Jurjani AH. *Zakhira Khwaarzam Shahi* (Urdu trans. by Khan HH). New Delhi: Idara Kitab ul Shifa; 2010.
12. Chughtaani HGM, Chughtaani HF. *Rahnumae Aqaqeer*. 2nd Vol. New Delhi: Ajaz Publishing House; 2004.
13. Khan A. *Al Akseer* (Urdu trans. by Kabeeruddin). 1st ed. New Delhi: Idara Kitab al Shifa; 2011.
14. Türk G, Sönmez M, Aydın M, Yüce A, Gür S, Yüksel M, et al. Effects of pomegranate juice consumption on sperm quality, spermatogenic cell density, antioxidant activity and testosterone level in male rats. *Clin Nutr*. 2008;27:289–96. [\[DOI\]](#) [\[PubMed\]](#)
15. Garachh D, Patel A, Chakraborty M, Kamath J. Phytochemical and pharmacological profile of *Punica granatum*: An overview. *Int Res J Pharm*. 2012;3:65–8.
16. Melgarejo-Sánchez P, Núñez-Gómez D, Martínez-Nicolás JJ, Hernández F, Legua P, Melgarejo P. Pomegranate variety and pomegranate plant part, relevance from bioactive point of view: a review. *Bioresour Bioprocess*. 2021;8:2. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
17. Joshi C, Patel P, Kothari V. Anti-infective potential of hydroalcoholic extract of *Punica granatum* peel against gram-negative bacterial pathogens. *F1000Res*. 2019;8:70. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
18. Choi JG, Kang OH, Lee YS, Chae HS, Oh YC, Brice OO, et al. In Vitro and In Vivo Antibacterial Activity of *Punica granatum* Peel Ethanol Extract against *Salmonella*. *Evid Based Complement Alternat Med*. 2011;2011:690518. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
19. Tito A, Colantuono A, Pirone L, Pedone E, Intartaglia D, Giamundo G, et al. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (*in vitro*): A Promising Source of Novel Antiviral Drugs. *Front Chem*. 2021;9:638187. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
20. Gharib E, Montasser Kouhsari S. Study of the Antidiabetic Activity of *Punica granatum* L. Fruits Aqueous Extract on the Alloxan-Diabetic Wistar Rats. *Iran J Pharm Res*. 2019;18:358–68. [\[PubMed\]](#) [\[PMC\]](#)
21. Kumar M, Dandapat S, Sinha MP. Hepatoprotective activity of *Punica granatum* leaf extract against carbon tetrachloride induced hepatotoxicity in rats. *Balneo Res J*. 2018;9:24–7. [\[DOI\]](#)
22. Sarkari Q. New Delhi: CCRUM. 2006.
23. Kabeeruddin HM. *Bayaze Kabeer*. New Delhi: Idara Kitab ul Shifa; 2014.
24. Lei F, Zhang XN, Wang W, Xing DM, Xie WD, Su H, et al. Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. *Int J Obes (Lond)*. 2007;31:1023–9. [\[DOI\]](#) [\[PubMed\]](#)
25. Wang Y, Huang M, Yang X, Yang Z, Li L, Mei J. Supplementing punicalagin reduces oxidative stress markers and restores angiogenic balance in a rat model of pregnancy-induced hypertension. *Korean J Physiol Pharmacol*. 2018;22:409–17. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
26. Sumner MD, Elliott-Eller M, Weidner G, Daubenmier JJ, Chew MH, Marlin R, et al. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. *Am J Cardiol*. 2005;96:810–4. [\[DOI\]](#) [\[PubMed\]](#)
27. Hameed HA. *Hamdard Pharmacopeia*. New Delhi; 1924.

28. Viuda-Martos M, Fernández-López J, Pérez-Álvarez JA. Pomegranate and its Many Functional Components as Related to Human Health: A Review. *Compr Rev Food Sci Food Saf.* 2010;9:635–54. [\[DOI\]](#) [\[PubMed\]](#)
29. Syed QA, Batool Z, Shukat R, Zahoor T. Nutritional and therapeutic properties of pomegranate. *Schol J Food Nutr.* 2018;1:115–20. [\[DOI\]](#)
30. Zarfeshany A, Asgary S, Javanmard SH. Potent health effects of pomegranate. *Adv Biomed Res.* 2014;3:100. [\[DOI\]](#)
31. Sreekumar S, Sithul H, Muraleedharan P, Azeez JM, Sreeharshan S. Pomegranate fruit as a rich source of biologically active compounds. *Biomed Res Int.* 2014;2014:686921. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
32. Evans WC. *Trease and Evans' Pharmacognosy.* 15th ed. New Delhi: Saunders an imprint of Elsevier; 2008.
33. Saeed M, Naveed M, BiBi J, Kamboh AA, Arain MA, Shah QA, et al. The Promising Pharmacological Effects and Therapeutic/Medicinal Applications of *Punica Granatum L.* (Pomegranate) as a Functional Food in Humans and Animals. *Recent Pat Inflamm Allergy Drug Discov.* 2018;12:24–38. [\[DOI\]](#) [\[PubMed\]](#)
34. Aviram M, Rosenblat M. Pomegranate Protection against Cardiovascular Diseases. *Evid Based Complement Alternat Med.* 2012;2012:382763. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
35. Sohrab G, Ebrahimof S, Sotoudeh G, Neyestani TR, Angoorani P, Hedayati M, et al. Effects of pomegranate juice consumption on oxidative stress in patients with type 2 diabetes: a single-blind, randomized clinical trial. *Int J Food Sci Nutr.* 2017;68:249–55. [\[DOI\]](#) [\[PubMed\]](#)
36. Stockton A, Farhat G, McDougall GJ, Al-Dujaili EAS. Effect of pomegranate extract on blood pressure and anthropometry in adults: a double-blind placebo-controlled randomised clinical trial. *J Nutr Sci.* 2017;6:e39. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
37. Taheri Rouhi SZ, Sarker MMR, Rahmat A, Alkahtani SA, Othman F. The effect of pomegranate fresh juice versus pomegranate seed powder on metabolic indices, lipid profile, inflammatory biomarkers, and the histopathology of pancreatic islets of Langerhans in streptozotocin-nicotinamide induced type 2 diabetic Sprague-Dawley rats. *BMC Complement Altern Med.* 2017;17:156. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
38. Al-Jarallah A, Igdoura F, Zhang Y, Tenedero CB, White EJ, MacDonald ME, et al. The effect of pomegranate extract on coronary artery atherosclerosis in SR-BI/APOE double knockout mice. *Atherosclerosis.* 2013;228:80–9. [\[DOI\]](#) [\[PubMed\]](#)
39. Bialonska D, Kasimsetty SG, Schrader KK, Ferreira D. The effect of pomegranate (*Punica granatum L.*) byproducts and ellagitannins on the growth of human gut bacteria. *J Agric Food Chem.* 2009;57:8344–9. [\[DOI\]](#) [\[PubMed\]](#)
40. Moazzen H, Alizadeh M. Effects of Pomegranate Juice on Cardiovascular Risk Factors in Patients with Metabolic Syndrome: a Double-Blinded, Randomized Crossover Controlled Trial. *Plant Foods Hum Nutr.* 2017;72:126–33. [\[DOI\]](#) [\[PubMed\]](#)
41. Hosseini B, Saedisomeolia A, Wood LG, Yaseri M, Tavasoli S. Effects of pomegranate extract supplementation on inflammation in overweight and obese individuals: A randomized controlled clinical trial. *Complement Ther Clin Pract.* 2016;22:44–50. [\[DOI\]](#) [\[PubMed\]](#)
42. Esmailzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L. Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. *J Med Food.* 2004;7:305–8. [\[DOI\]](#) [\[PubMed\]](#)
43. Reguero M, Gómez de Cedrón M, Sierra-Ramírez A, Fernández-Marcos PJ, Reglero G, Quintela JC, et al. Pomegranate Extract Augments Energy Expenditure Counteracting the Metabolic Stress Associated with High-Fat-Diet-Induced Obesity. *Int J Mol Sci.* 2022;23:10460. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
44. Lee HJ, Jung YH, Choi GE, Kim JS, Chae CW, Lim JR, et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis. *Cell Death Differ.* 2021;28:184–202. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)

45. Braidy N, Selvaraju S, Essa MM, Vaishnav R, Al-Adawi S, Al-Asmi A, et al. Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons. *Oxid Med Cell Longev*. 2013;2013:685909. [DOI] [PubMed] [PMC]
46. Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav R, Braidy N, et al. Pomegranate from Oman Alleviates the Brain Oxidative Damage in Transgenic Mouse Model of Alzheimer's disease. *J Tradit Complement Med*. 2014;4:232–8. [DOI] [PubMed] [PMC]
47. Mehdi A, Lamiae B, Samira B, Ramchoun M, Abdelouahed K, Tamas F, et al. Pomegranate (*Punica granatum* L.) Attenuates Neuroinflammation Involved in Neurodegenerative Diseases. *Foods*. 2022; 11:2570. [DOI] [PubMed] [PMC]
48. Kim KB, Lee S, Kim JH. Neuroprotective effects of urolithin A on H₂O₂-induced oxidative stress-mediated apoptosis in SK-N-MC cells. *Nutr Res Pract*. 2020;14:3–11. [DOI] [PubMed] [PMC]
49. Adhami VM, Khan N, Mukhtar H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. *Nutr Cancer*. 2009;61:811–5. [DOI] [PubMed] [PMC]
50. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. *Clin Cancer Res*. 2006;12:4018–26. [DOI] [PubMed]
51. Guzmán-Lorite M, Muñoz-Moreno L, Marina ML, Carmena MJ, García MC. Assessment of the effect of pomegranate seed extracts on prostate cancer through cellular and animal models. *Sci Rep*. 2025;15: 20379. [DOI] [PubMed] [PMC]
52. Usha T, Middha SK, Sidhalinghamurthy KR. Pomegranate peel and its anticancer activity: A mechanism-based review. In: *Plant-derived Bioactives: Chemistry and mode of action*. Springer; 2020. pp. 223–50. [DOI]
53. Nasiri E, Hosseinimehr SJ, Akbari J, Azadbakht M, Azizi S. The Effects of *Punica granatum* Flower Extract on Skin Injuries Induced by Burn in Rats. *Adv Pharmacol Sci*. 2017;2017:3059745. [DOI] [PubMed] [PMC]
54. Baghdadi IH. Kitabul Mukhtarat fil Tib. In: Urdu translation by CCRUM. 3rd Part. New Delhi; 2004. p.184.
55. Farhat G, Malla J, Vadher J, Al-Dujaili EAS. Effects of Pomegranate Extract on Inflammatory Markers and Cardiometabolic Risk Factors in Adults Aged 55-70 Years: A Randomised Controlled Parallel Trial. *Nutrients*. 2025;17:1235. [DOI] [PubMed] [PMC]
56. Houston DM, Bugert J, Denyer SP, Heard CM. Anti-inflammatory activity of *Punica granatum* L. (Pomegranate) rind extracts applied topically to ex vivo skin. *Eur J Pharm Biopharm*. 2017;112: 30–7. [DOI] [PubMed]
57. Abdolhosseini S, Hashem-Dabaghian F, Mokaberinejad R, Sadeghpour O, Mehrabani M. Effects of pomegranate and spearmint syrup on nausea and vomiting during pregnancy: a randomized controlled clinical trial. *Iran Red Cresc Med J*. 2017;19:13542. [DOI]
58. Ishtiyag MZ, Abbas M. Assessment of Antiemetic Activity of Methanolic Peel extract of *Punica granatum* Linn by Chick emesis model. *Heal J Pharm Allied Sci*. 2018;1:38–43.
59. Qnais EY, Elokda AS, Ghalyun YYA, Abdulla FA. Antidiarrheal Activity of the Aqueous extract of *Punica granatum* (Pomegranate) peels. *Pharm Biol*. 2007;45:715–20. [DOI]
60. Baravkar AA, Shende MV, Nalawade NA, Aher NB. Comparative *in vitro* Anthelmintic Activity of Aqueous and Organic Extract of Root and Bark of *Punica Granatum* Linn. *Int J Curr Res Rev*. 2020;12: 16–8. [DOI]
61. Esmaeilinezhad Z, Babajafari S, Sohrabi Z, Eskandari MH, Amooee S, Barati-Boldaji R. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: A randomized, triple blind, controlled trial. *Nutr Metab Cardiovasc Dis*. 2019;29:201–8. [DOI] [PubMed]

62. Ross MM, Cherkerzian S, Mikulis ND, Turner D, Robinson J, Inder TE, et al. A randomized controlled trial investigating the impact of maternal dietary supplementation with pomegranate juice on brain injury in infants with IUGR. *Sci Rep*. 2021;11:3569. [DOI] [PubMed] [PMC]
63. Manthou E, Georgakouli K, Deli CK, Sotiropoulos A, Fatouros IG, Kouretas D, et al. Effect of pomegranate juice consumption on biochemical parameters and complete blood count. *Exp Ther Med*. 2017;14:1756–62. [DOI] [PubMed] [PMC]
64. Chidambara Murthy KN, Jayaprakasha GK, Singh RP. Studies on antioxidant activity of pomegranate (*Punica granatum*) peel extract using in vivo models. *J Agric Food Chem*. 2002;50:4791–5. [DOI] [PubMed]
65. Es-Haghe Ashtean S, Vahid Dastjerdi M, Tabarrai M, Nejatbakhsh F, Sadati Lamardi SN, Rahmani A, et al. Effectiveness of Persian Golnar on Excessive Menstrual Bleeding in Women with Abnormal Uterine Bleeding, Compared to Tranexamic Acid: A Triple-Blind, Randomized Equivalence Trial. *Evid Based Complement Alternat Med*. 2023;2023:5355993. [DOI] [PubMed] [PMC]
66. Goshtasebi A, Mazari Z, Behboudi Gandevani S, Naseri M. Anti-hemorrhagic activity of *Punica granatum* L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double-blind, randomized controlled trial. *Med J Islam Repub Iran*. 2015;29:199. [PubMed] [PMC]
67. Gandhi GR, Antony PJ, Ceasar SA, Vasconcelos ABS, Montalvão MM, Farias de Franca MN, et al. Health functions and related molecular mechanisms of ellagitannin-derived urolithins. *Crit Rev Food Sci Nutr*. 2024;64:280–310. [DOI] [PubMed]
68. Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Félix AA, et al. Urolithin A induces mitophagy and prolongs lifespan in *C. elegans* and increases muscle function in rodents. *Nat Med*. 2016;22:879–88. [DOI] [PubMed]
69. Du J, Wang H, Zhong L, Wei S, Min X, Deng H, et al. Bioactivity and biomedical applications of pomegranate peel extract: a comprehensive review. *Front Pharmacol*. 2025;16:1569141. [DOI] [PubMed] [PMC]
70. Henning SM, Yang J, Lee RP, Huang J, Hsu M, Thames G, et al. Pomegranate Juice and Extract Consumption Increases the Resistance to UVB-induced Erythema and Changes the Skin Microbiome in Healthy Women: a Randomized Controlled Trial. *Sci Rep*. 2019;9:14528. [DOI] [PubMed] [PMC]
71. Hasanpour M, Saberi S, Iranshahi M. Metabolic Profiling and Untargeted ¹H-NMR-Based Metabolomics Study of Different Iranian Pomegranate (*Punica granatum*) Ecotypes. *Planta Med*. 2020;86:212–9. [DOI] [PubMed]
72. Villa-Ruano N, Rosas-Bautista A, Rico-Arzate E, Cruz-Narvaez Y, Zepeda-Vallejo LG, Lalaleo L, et al. Study of nutritional quality of pomegranate (*Punica granatum* L.) juice using ¹H NMR-based metabolomic approach: A comparison between conventionally and organically grown fruits. *LWT-Food Sci Technol*. 2020;134:110222. [DOI]
73. Polcaro LM, Samani MR, Piacente S, Masullo M. Development of a New Extraction Method for Pomegranate and Metabolite Profiling by a LC-MS and ¹H NMR Combined Approach. *Foods*. 2024;13:1429. [DOI] [PubMed] [PMC]
74. Cirillo A, Magri A, Scognamiglio M, D'Abrosca B, D'Abrosca B, Petriccione M, et al. Evaluation of morphological, qualitative, and metabolomic traits during fruit ripening in pomegranate (*Punica granatum* L.). *Hortic*. 2022;8:384. [DOI]
75. Girelli CR, Papadia P, Pagano F, Miglietta PP, Cardinale M, Rustioni L. Metabolomic NMR analysis and organoleptic perceptions of pomegranate wines: Influence of cultivar and yeast on the product characteristics. *Heliyon*. 2023;9:e16774. [DOI] [PubMed] [PMC]
76. Hendre AS, Phatak RS, Durgawale PP. Phytochemical Composition of Methanolic Extract of Pomegranate Flower Petals (*Punica granatum*) by GC-MS Analysis. *Int J Pharm Sci Rev Res*. 2015;35:201–2.

77. Calani L, Beghè D, Mena P, Del Rio D, Bruni R, Fabbri A, et al. Ultra-HPLC-MS(n) (Poly)phenolic profiling and chemometric analysis of juices from ancient *Punica granatum* L. Cultivars: a nontargeted approach. *J Agric Food Chem*. 2013;61:5600–9. [DOI] [PubMed]
78. Kumar KA, Vijayalakshmi K. GC-MS analysis of phytochemical constituents in ethanolic extract of *Punica granatum* peel and *Vitis vinifera* seeds. *Int J Pharm Bio Sci*. 2011;2:461–8.
79. Gómez-Bellot MJ, García CJ, Parra A, Vallejo F, Ortuño MF. Influence of drought stress on increasing bioactive compounds of pomegranate (*Punica granatum* L.) juice. Exploratory study using LC–MS-based untargeted metabolomics approach. *Eur Food Res Technol*. 2023;249:2947–56. [DOI]
80. Attia EA. Antimicrobial Activity and Bio-active compounds analysis in Ethanolic plant extracts of *Punica Granatum* (Pomegranate) using GC-MS. *Egypt J Exp Biol*. 2019;15:325–31. [DOI]
81. Man G, Xu L, Wang Y, Liao X, Xu Z. Profiling Phenolic Composition in Pomegranate Peel From Nine Selected Cultivars Using UHPLC-QTOF-MS and UPLC-QQQ-MS. *Front Nutr*. 2022;8:807447. [DOI] [PubMed] [PMC]
82. Liu Y, Seeram NP. Liquid chromatography coupled with time-of-flight tandem mass spectrometry for comprehensive phenolic characterization of pomegranate fruit and flower extracts used as ingredients in botanical dietary supplements. *J Sep Sci*. 2018;41:3022–33. [DOI] [PubMed] [PMC]
83. Farag SM, Hussein MA, Hafez SE, Khaled AS, Kamel OM, Zyaan OH. Larvicidal, biological, and histopathological alterations induced by pomegranate peel extract, *Punica granatum* against *Culex pipiens* L. (Diptera: Culicidae). *Egypt J Aqua Biol Fish*. 2021;25:139–61.
84. Yisimayili Z, Abdulla R, Tian Q, Wang Y, Chen M, Sun Z, et al. A comprehensive study of pomegranate flowers polyphenols and metabolites in rat biological samples by high-performance liquid chromatography quadrupole time-of-flight mass spectrometry. *J Chromatogr A*. 2019;1604:460472. [DOI] [PubMed]
85. Yisimayili Z, Chao Z. A review on phytochemicals, metabolic profiles and pharmacokinetics studies of the different parts (juice, seeds, peel, flowers, leaves and bark) of pomegranate (*Punica granatum* L.). *Food Chem*. 2022;395:133600. [DOI] [PubMed]
86. Selma MV, González-Sarrías A, Salas-Salvadó J, Andrés-Lacueva C, Alasalvar C, Örem A, et al. The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome. *Clin Nutr*. 2018;37:897–905. [DOI] [PubMed]
87. Nuñez-Sánchez MA, García-Villalba R, Monedero-Saiz T, García-Talavera NV, Gómez-Sánchez MB, Sánchez-Álvarez C, et al. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. *Mol Nutr Food Res*. 2014;58:1199–211. [DOI] [PubMed]
88. García-Villalba R, Giménez-Bastida JA, Cortés-Martín A, Ávila-Gálvez MÁ, Tomás-Barberán FA, Selma MV, et al. Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota. *Mol Nutr Food Res*. 2022;66:e2101019. [DOI] [PubMed] [PMC]
89. Bialonska D, Kasimsetty SG, Khan SI, Ferreira D. Urolithins, intestinal microbial metabolites of Pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay. *J Agric Food Chem*. 2009;57:10181–6. [DOI] [PubMed]
90. Espín JC, Larrosa M, García-Conesa MT, Tomás-Barberán F. Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. *Evid Based Complement Alternat Med*. 2013;2013:270418. [DOI] [PubMed] [PMC]
91. Benedetti G, Zabini F, Tagliavento L, Meneguzzo F, Calderone V, Testai L. An Overview of the Health Benefits, Extraction Methods and Improving the Properties of Pomegranate. *Antioxidants* (Basel). 2023;12:1351. [DOI] [PubMed] [PMC]
92. Kmail A. Punicalagin: Structure, Metabolism, and Therapeutic Potential of a Major Pomegranate Ellagitannin. *J App Pharm Sci*. 2026;22313354261438279. [DOI]

93. Moccia F, Flores-Gallegos AC, Chávez-González ML, Sepúlveda L, Marzorati S, Verotta L, et al. Ellagic Acid Recovery by Solid State Fermentation of Pomegranate Wastes by *Aspergillus niger* and *Saccharomyces cerevisiae*: A Comparison. *Molecules*. 2019;24:3689. [DOI] [PubMed] [PMC]
94. DaSilva NA, Nahar PP, Ma H, Eid A, Wei Z, Meschwitz S, et al. Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. *Nutr Neurosci*. 2019;22:185–95. [DOI] [PubMed]
95. Tomás-Barberán FA, González-Sarrías A, García-Villalba R, Núñez-Sánchez MA, Selma MV, García-Conesa MT, et al. Urolithins, the rescue of "old" metabolites to understand a "new" concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. *Mol Nutr Food Res*. 2017;61. [DOI] [PubMed]
96. Singh A, D'Amico D, Andreux PA, Dunngalvin G, Kern T, Blanco-Bose W, et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. *Eur J Clin Nutr*. 2022;76:297–308. [DOI] [PubMed] [PMC]
97. Lin IC, Wu JY, Fang CY, Wang SC, Liu YW, Ho ST. Absorption and Metabolism of Urolithin A and Ellagic Acid in Mice and Their Cytotoxicity in Human Colorectal Cancer Cells. *Evid Based Complement Alternat Med*. 2023;2023:8264716. [DOI] [PubMed] [PMC]
98. Henning SM, Summanen PH, Lee RP, Yang J, Finegold SM, Heber D, et al. Pomegranate ellagitannins stimulate the growth of *Akkermansia muciniphila* in vivo. *Anaerobe*. 2017;43:56–60. [DOI] [PubMed]
99. Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI. Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. *Front Nutr*. 2021;8:647582. [DOI] [PubMed] [PMC]
100. Li Z, Henning SM, Lee RP, Lu QY, Summanen PH, Thames G, et al. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. *Food Funct*. 2015;6:2487–95. [DOI] [PubMed]
101. Kujawska M, Jourdes M, Kurpik M, Szulc M, Szaefer H, Chmielarz P, et al. Neuroprotective Effects of Pomegranate Juice against Parkinson's Disease and Presence of Ellagitannins-Derived Metabolite-Urolithin A-In the Brain. *Int J Mol Sci*. 2019;21:202. [DOI] [PubMed] [PMC]
102. Seeram NP, Zhang Y, McKeever R, Henning SM, Lee RP, Suchard MA, et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. *J Med Food*. 2008;11:390–4. [DOI] [PubMed] [PMC]
103. Nasef NA, Rosendale D, McKeen S. Ellagitannins. In: Jafari SM, Rashidinejad A, Simal-Gandara J, editors. *Handbook of Food Bioactive Ingredients*. Springer; 2023. pp. 407–26. [DOI]
104. López de Las Hazas MC, Tomé-Carneiro J, Del Pozo-Acebo L, Del Saz-Lara A, Chapado LA, Balaguer L, et al. Therapeutic potential of plant-derived extracellular vesicles as nanocarriers for exogenous miRNAs. *Pharmacol Res*. 2023;198:106999. [DOI] [PubMed]
105. Sánchez-López CM, Manzaneque-López MC, Pérez-Bermúdez P, Soler C, Marcilla A. Characterization and bioactivity of extracellular vesicles isolated from pomegranate. *Food Funct*. 2022;13:12870–82. [DOI] [PubMed]